MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin

Table 1 Clinical background of 5 patients with advanced gastric cancer

Age	Sex	TNM stage	Histology of tumor	Drug regimen of HIPEC	Duration of HIPEC (min)	ECOG	HIPEC temperature (°C)	Time of surgery (h)	Following time (yr) and results
49	Male	T4aN1M0	Poorly-differentiated adenocarcinoma	5-Fu cisplatin	60	1	43	3	1, alive
56	Male	T3N2M0	Moderately-differentiated adenocarcinoma	5-Fu cisplatin	60	2	43	3.5	1.5, alive
67	Female	T4N2M0	Poorly-differentiated adenocarcinoma	5-Fu cisplatin	60	0	43	3.8	1, dead
53	Male	T3N1M0	Poorly-differentiated adenocarcinoma	5-Fu cisplatin	60	1	43	4	1.2, dead
62	Male	T4bN0M0	Moderately-differentiated adenocarcinoma	5-Fu cisplatin	60	2	43	3	0.5, alive

ECOG: Eastern Cooperative Oncology Group; HIPEC: Hyperthermic intraperitoneal chemotherapy.

Table 2 Three-fold upregulation of microRNAs in advanced gastric cancer tumor serums

MicroRNA	Raising multiples	P value
miR-218	8.419	0.004
miR-135b	5.317	0.003
miR-135a	4.788	0.016
miR-433	4.401	0.025
miR-409	4.389	0.039
miR-96	4.280	0.050
miR-647	4.113	0.067
miR-376a	3.940	0.003
miR-4326	3.899	0.045
miR-1306	3.705	0.021
miR-937	3.699	0.028
miR-326	3.661	0.007
miR-214	3.500	0.001
miR-377	3.403	0.009
miR-661	3.397	0.005
miR-3678	3.235	0.011
miR-632	3.226	0.035
miR-154	3.140	0.028
miR-134	3.119	0.027